Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2019 Earnings Conference Call Transcript
May 09, 2019 • 04:30 pm ET
Good day, and welcome to the Inovio Pharmaceuticals First Quarter 2019 Financial Results Conference Call. All participants will be in a listen-only mode. (Operator Instructions) Please note this event is being recorded.
I'd now like to turn the conference over to Ben Matone, Director of Investor Relations. Please go ahead, sir.
Thank you, operator. Good afternoon everyone and welcome to the Inovio Pharmaceuticals first quarter 2019 investor conference call. With me today are, Inovio's President and CEO, Dr. J. Joseph Kim, our Chief Financial Officer, Peter Kies and our Chief Scientific Officer, Dr. Laurent Humeau. Today's call is also being webcast live on our website ir.inovio.com and a replay of today's call will be made available. Following a general business update, we will conduct a question-and-answer segment which will be reserved for equity research analysts.
As a reminder, we will be making certain forward-looking statements that relate to our business, which include our plans to develop our immunotherapy platform in combination with our proprietary delivery devices as well as developments and timing of certain clinical data readouts and our capital resources. These statements involve certain assumptions, risks and uncertainties and could cause actual results to differ materially from these statements.
All of these statements are based on the beliefs and expectations of management, as of today. We assume no obligation to revise or update forward-looking statements whether as a result of new information, future events or otherwise. Investors should read carefully the risks and uncertainty described in today's press release, which is posted on our website as well as the risk factors included in our filings with the SEC.
With that, I would like to turn the call over to our CEO, Dr. J. Joseph Kim.
J. Joseph Kim
Thanks, Ben, and good afternoon, everyone. I will first provide you today with my statistical review and then our CFO, Peter Kies will detail our financials. Our Chief Scientific Officer Dr. Laurent Humeau, also joins our call today. Dr. Humeau will update you on our exciting R&D efforts with focus on our dMAb and dBiTE programs. Our new area we're extremely excited about, given the potential these technologies have for both patients and our shareholders.
I would like to start off by saying that Inovio remains on track on meeting our clinical development timelines along with our business development and commercial plans. You've heard me say many times before Inovio aims to be the go-to-player for treating all HPV-related diseases from pre-cancers to cancer. We're an aggressive management team that isn't just waiting for our Phase 3 VGX-3100 data to come in. To that end, we have applied for and were granted an Advanced Therapy Medicinal Product certificate by the European Medicines Agency.
Second, we continue to make a significant advancement in our efforts to develop a pre-treatment biomarker kit that could target patients most likely to respond positively to treatment with VGX-3100, which in turn can potentially enhance absolute efficacy of the product. I'll tell you what each of these strategic activities mean for